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Heart failure is a clinical syndrome that is as-
sociated with various cardiovascular diseases 
such as hypertension and myocardial infarction 
(Libby and Braunwald, 2008). Comprehensive 
management using current therapeutic options 
can markedly reduce the morbidity and mor-
tality of heart failure. Large-scale clinical trials 
of drugs targeting neurohormonal mechanisms, 
such as angiotensin-converting enzyme inhibi-
tors  and    blockers,  have  shown  that  such 
treatment is effective for reducing mortality in 
patients with heart failure (Garg and Yusuf, 1995; 
McMurray, 1999; Goldstein, 2002). However, 
heart failure is still one of the leading causes of 
death worldwide (Libby and Braunwald, 2008), 
so it is important to investigate the underlying 
mechanisms of this condition and develop more 
effective treatments.
Arachidonic acid is a free fatty acid that, when 
liberated from cell membranes, can be metabo-
lized by cyclooxygenase, cytochrome p450, and 
lipoxygenase (LOX) to form biologically active 
products such as prostaglandins, leukotrienes, 
and hydroxy-eicosatetraenoic acids (HETEs; 
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To identify a novel target for the treatment of heart failure, we examined gene expression 
in the failing heart. Among the genes analyzed, Alox15 encoding the protein 12/15 lipoxy-
genase (LOX) was markedly up-regulated in heart failure. To determine whether increased 
expression of 12/15-LOX causes heart failure, we established transgenic mice that overex-
pressed 12/15-LOX in cardiomyocytes. Echocardiography showed that Alox15 transgenic 
mice developed systolic dysfunction. Cardiac fibrosis increased in Alox15 transgenic mice 
with advancing age and was associated with the infiltration of macrophages. Consistent 
with these observations, cardiac expression of monocyte chemoattractant protein 1 (MCP-1) 
was up-regulated in Alox15 transgenic mice compared with wild-type mice. Treatment with 
12-hydroxy-eicosatetraenoic acid, a major metabolite of 12/15-LOX, increased MCP-1 
expression in cardiac fibroblasts and endothelial cells but not in cardiomyocytes. Inhibi-
tion of MCP-1 reduced the infiltration of macrophages into the myocardium and prevented 
both systolic dysfunction and cardiac fibrosis in Alox15 transgenic mice. Likewise, disrup-
tion of 12/15-LOX significantly reduced cardiac MCP-1 expression and macrophage infil-
tration, thereby improving systolic dysfunction induced by chronic pressure overload. Our 
results suggest that cardiac 12/15-LOX is involved in the development of heart failure and 
that inhibition of 12/15-LOX could be a novel treatment for this condition.
© 2009 Kayama et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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genes analyzed, Alox15 encoding the protein 12/15-LOX was 
most markedly up-regulated in failing hearts compared with 
control hearts (Fig. 1 A). Northern blot analysis confirmed 
that the messenger RNA (mRNA) for this gene was strik-
ingly elevated in heart failure (Fig. 1 B). Immunohistochem-
istry showed that expression of 12/15-LOX was specifically 
up-regulated in cardiomyocytes of failing hearts (Fig. 1 C).
To  determine  whether  increased  expression  of  12/15-
LOX could cause heart failure, we established Alox15 trans-
genic mice in which expression of the murine Alox15 gene 
was under the control of the -cardiac myosin heavy chain 
promoter. We obtained two lines of transgenic mice, both 
of which showed an 10-fold increase in the myocardial 
expression of 12/15-LOX compared with their WT litter-
mates (Fig. 2 A; and Fig. S1, A and B). Histological exam-
ination  also  indicated  that  the  transgenic  mice  showed 
increased myocardial expression of 12/15-LOX (Fig. 2 B 
and Fig. S1 C). Consequently, production of 12(S)-HETE 
and 15(S)-HETE was significantly increased in the hearts of 
Alox15 transgenic mice (Fig. 2 C). The left ventricular dia-
stolic dimension (LVDd) was increased and left ventricular 
fractional shortening (FS) was decreased in Alox15 trans-
genic mice from 26 wk of age compared with their WT lit-
termates (Fig. 2 D). These changes observed in the transgenic 
animals showed further progression with aging (Fig. 2 D). 
Histological examination revealed that cardiac fibrosis was 
increased in Alox15 transgenic mice and that this fibrosis also 
progressed  with  advancing  age  and  was  associated  with   
infiltration of macrophages (Fig. 2, E and F). There was no 
difference in blood pressure between Alox15 transgenic mice 
and their WT littermates at 16 or 48 wk of age (Fig. S1 D). 
The cardiac changes were similar in two independent lines 
of Alox15 transgenic mice, suggesting that increased expres-
sion of 12/15-LOX might cause heart failure by inducing 
myocardial inflammation.
12/15-LOX induces cardiac inflammation
To investigate the mechanism by which cardiac infiltration of 
macrophages was increased in Alox15 transgenic mice, we 
examined the expression of various proinflammatory cyto-
kines that are thought to be macrophage chemoattractants by 
the ribonuclease protection assay. We found that cardiac ex-
pression  of  Ccl2  (MCP-1)  was  significantly  increased  in 
Alox15 transgenic mice compared with WT mice (Fig. 3 A). 
In vitro experiments demonstrated that treatment with 12(S)-
HETE increased Ccl2 expression by cardiac fibroblasts and 
endothelial cells (Fig. 3, B and C), whereas there was no ef-
fect when cardiomyocytes were treated with 12(S)-HETE 
(Fig. 3 D). Moreover, incubation of COS7 cells with 12(S)-
HETE significantly increased the activity of nuclear factor 
B, a transcription factor that regulates the induction of pro-
inflammatory cytokines including MCP-1 (Fig. 3 E). In con-
trast, 12(S)-HETE did not affect the activity of this factor 
when cells were transfected with a reporter plasmid contain-
ing mutant B binding sites (Fig. 3 E). These results suggest 
that increased production of 12(S)-HETE by cardiomyocytes 
Kudo and Murakami, 2002). LOXs are a family of lipid-
peroxidizing enzymes that oxidize free and esterified poly-
enolic fatty acids to form the corresponding hydroperoxy 
derivates (Kuhn and O’Donnell, 2006). The LOX enzymes 
are named according to the specific carbon atoms of arachi-
donic acid that are oxidized. Thus, 12/15-LOX is a member 
of the LOX family that catalyzes the step from arachidonic 
acid to 12(S)-HETE and 15(S)-HETE (Chen et al., 1994). 
12/15-LOX was originally isolated from porcine leukocytes 
(Yokoyama et al., 1986), but its tissue distribution is now 
known  to  be  relatively  wide,  including  blood  vessels,  the 
brain, and the kidneys (Kuhn and O’Donnell, 2006). Several 
lines of evidence have suggested that 12/15-LOX may play an 
important role in the development of atherosclerosis, diabetes, 
and neurodegenerative disease (Natarajan and Nadler, 2004; 
Kuhn and O’Donnell, 2006). For example, disruption of the 
gene for 12/15-LOX in mice significantly reduces the onset 
of atherosclerosis (Cyrus et al., 1999, 2001; George et al., 
2001), whereas an increase of 12/15-LOX expression in 
mice promotes monocyte–endothelial cell interactions that 
lead to atherogenesis (Hatley et al., 2003; Reilly et al., 2004; 
Bolick et al., 2005). Several studies have shown that mono-
cyte 12/15-LOX mediates the oxidative modification of low-
density lipoprotein (McNally et al., 1990; Sakashita et al., 
1999; Zhu et al., 2003b). An increase of 12/15-LOX activity 
in vessel walls also contributes to atherogenesis by impairing 
the macrophage cholesterol efflux pathway (Nagelin et al., 
2008). Interestingly, mice with deficiency of 12/15-LOX are 
resistant to the development of streptozotocin-induced diabe-
tes (Bleich et al., 1999) and autoimmune diabetes (McDuffie 
et al., 2008). However, there is currently little evidence that 
12/15-LOX has a role in heart failure.
In the present study, we showed that cardiac 12/15-LOX 
induces inflammation that is involved in heart failure. We 
found that 12/15-LOX expression was markedly increased in 
the failing heart. Increased expression of this enzyme up-
regulates monocyte chemoattractant protein 1 (MCP-1) and 
promotes the infiltration of macrophages into the heart, thereby 
causing cardiac fibrosis and systolic dysfunction. Conversely, 
disruption of Alox15 reduces cardiac MCP-1 expression and 
macrophage infiltration, thereby improving systolic dysfunc-
tion induced by chronic pressure overload. These findings 
suggest that inhibition of 12/15-LOX could be a novel treat-
ment for heart failure.
RESULTS
Increased expression of 12/15-LOX causes heart failure
To clarify the molecular mechanisms of heart failure, we 
performed microarray analysis using cardiac tissue samples 
obtained from a hypertensive heart failure model (Dahl salt-
sensitive rats). Approximately 300 genes showed significant 
changes of expression in failing hearts compared with control 
hearts. For example, fetal genes, such as the natriuretic pep-
tide genes and the -type myosin heavy chain gene, were 
up-regulated, whereas cardioprotective genes, such as heat 
shock proteins, were down-regulated (Table S1). Among the JEM VOL. 206, July 6, 2009 
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was a significant increase in the blood level of 7ND and ele-
vation of plasma human MCP-1 (Fig. 4 A and Fig. S2). This 
mutant MCP-1 binds to the MCP-1 receptor (chemokine 
receptor 2) and inhibits downstream signaling (Egashira, 2003). 
Consequently, injection of the 7ND plasmid has been re-
ported to suppress MCP-1 activity in vivo and inhibit the 
development of atherosclerosis (Ni et al., 2001), as well as 
inhibiting cardiac remodelling after myocardial infarction 
(Hayashidani et al., 2003). In agreement with these results, 
causes up-regulation of MCP-1 in other cells of the heart, 
thereby leading to accumulation of macrophages.
To investigate the relationship between up-regulation of 
MCP-1 and heart failure, we examined the effect of MCP-1 
inhibition on cardiac dysfunction in Alox15 transgenic mice. 
We injected an expression vector encoding mutant human 
MCP-1 with deletion of N-terminal amino acids (7ND plasmid; 
Egashira, 2003) or the empty vector (mock) into the thigh 
muscles of mice every 2 wk until 48 wk of age. The result 
Figure 1.  Expression of 12/15-LOX is up-regulated in the failing heart. (A) Dahl salt-sensitive rats were fed a low-sodium diet until the age of  
6 wk and then a high-sodium diet (8% NaCl) throughout the experimental period. In this model, prominent cardiac hypertrophy developed and left ven-
tricular systolic function was impaired by 17 wk of age. Rats fed a low-salt diet (0.3% NaCl) served as the control. The animals were sacrificed for gene 
chip analysis at 17 wk of age. Expression of Alox15 was markedly up-regulated in failing hearts (HF) compared with control hearts (Cont). (B) Northern 
blot analysis confirmed that the expression of mRNA for Alox15 was strikingly elevated in failing hearts. (C) Immunohistochemistry for 12/15-LOX in the 
heart at 17 wk of age. Expression of 12/15-LOX (red) was specifically up-regulated in cardiomyocytes (green) of failing hearts. Nuclei were stained with 
DAPI (blue). Bars, 20 µm. Normal rabbit serum was used as a negative control of polyclonal antibody against 12/15-LOX. Results in A are obtained from 
one experiment. Results in B and C are representative of three independent experiments.1568 12/15-LIPOXYGENASE IN HEART FAILURE | Kayama et al.
Figure 2.  Increased expression of 12/15-LOX causes heart failure. (A) Western blot analysis of 12/15-LOX expression in the hearts of WT and 
Alox15 transgenic (Tg) mice using anti–12/15-LOX antibody (12/15-LOX) or anti-HA antibody (HA). (B) Immunohistochemistry for 12/15-LOX (red) in the 
hearts of WT and Alox15 transgenic mice. Nuclei were stained with DAPI (blue). Bars, 40 µm. Results in A and B are representative of three independent 
experiments. (C) 12/15(S)-HETE levels in the hearts of WT and Alox15 transgenic mice. (D) Echocardiographic findings in WT and transgenic mice. The 
LVDd was increased and left ventricular FS was decreased in Alox15 transgenic mice compared with their WT littermates. These changes observed in the 
transgenic animals showed progression with aging. *, P < 0.05; **, P < 0.01 versus WT. Results in C and D represent the mean ± SEM of three independent 
experiments. C, n = 6; D, n = 14. (E) Masson trichrome staining (top) and immunohistochemistry for Mac3 (bottom) in the hearts of WT and transgenic 
mice at the ages of 16 wk (16w) and 48 wk (48w). Cardiac fibrosis was increased in Alox15 transgenic mice, and this fibrosis progressed with advancing 
age and was associated with infiltration of macrophages. Bars, 100 µm. Results are representative of three independent experiments. (F) The number of 
Mac3-positive cells in the hearts of WT and transgenic mice at the ages of 16 wk (16w) and 48 wk (48w). *, P < 0.01 versus WT (16w); #, P < 0.01 versus 
WT (48w); †, P < 0.01 versus transgenic (16w). Results represent the mean ± SEM of three independent experiments; n = 7.JEM VOL. 206, July 6, 2009 
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histological examination and echocardiography demonstrated 
that injection of this plasmid reduced the myocardial infiltra-
tion of macrophages in Alox15 transgenic mice, as well as 
preventing systolic dysfunction and left ventricular dilatation 
(Fig. 4, B and C). These results suggested that 12/15-LOX 
induces cardiac dysfunction by up-regulation of MCP-1 ex-
pression in the heart.
Cardiac expression of 12/15-LOX is up-regulated during 
pressure overload
To further investigate the role of 12/15-LOX in heart fail-
ure, we examined its cardiac expression in WT mice with 
severe transverse aortic constriction (TAC). In this model, 
cardiac hypertrophy gradually progresses to reach a peak on 
day 7 after TAC and then decreases afterward (not depicted). 
FS was preserved until day 7 but was significantly decreased 
on day 14 along with left ventricular dilatation (Fig. 5 A). 
Cardiac expression of Alox15 was significantly up-regulated 
after TAC (Fig. 5 B), and the production of both 12(S)-
HETE and 15(S)-HETE was increased in the heart (Fig. 5 C). 
Histological examination demonstrated an increase in the ex-
pression of 12/15-LOX by cardiomyocytes after TAC (Fig. 6 A 
and Fig. S3).
We next created Alox15-deficient mice with TAC and 
compared them to WT TAC mice. The increase of 12(S)-
HETE and 15(S)-HETE production after TAC was markedly 
attenuated by disruption of Alox15 (Fig. 6). Disruption of Alox15 
also significantly improved systolic dysfunction and prevented 
left ventricular dilatation in the presence of chronic pressure 
overload without any change of blood pressure (Fig. 5 A and 
Fig. S4), indicating that 12/15-LOX has an important role 
in the induction of cardiac dysfunction by pressure overload. 
To examine whether Alox15 deficiency could inhibit cardiac 
inflammation, we assessed the expression of Ccl2 and a mac-
rophage marker (Cd68) in the heart after TAC. Expression of 
both genes was increased by about threefold at 14 d after 
TAC. The increase of Ccl2 and Cd68 expression was signifi-
cantly inhibited by disruption of Alox15 (Fig. 6 C), suggesting 
that this gene has a crucial role in the development of heart 
failure by promoting cardiac inflammation.
DISCUSSION
We demonstrated a crucial role of 12/15-LOX–induced in-
flammation in the development of heart failure. Activation of 
this enzyme has been shown to promote neuronal death, 
whereas inhibition of 12/15-LOX protects against brain dam-
age caused by oxidative stress or ischemia by inhibiting neu-
ronal death (Lebeau et al., 2004; Jin et al., 2008; Seiler et al., 
2008). In contrast, treatment with 12(S)-HETE does not in-
duce the apoptosis of cultured cardiomyocytes (unpublished 
data). Indeed, few apoptotic cardiomyocytes were detected 
in the hearts of Alox15 transgenic mice even after the onset 
of systolic dysfunction (unpublished data). Instead, these mice 
showed an increase of macrophages infiltrating into the myo-
cardium, which was associated with cardiac fibrosis and sys-
tolic dysfunction. Our findings suggested that MCP-1 may 
Figure 3.  12/15-LOX up-regulates MCP-1 expression. (A) Expres-
sion of Ccl2 (MCP-1) was examined in the hearts of WT and 12/15-LOX 
transgenic (Tg) mice by the ribonuclease protection assay. The graph indi-
cates relative expression of Ccl2. Cardiac expression of Ccl2 was signifi-
cantly greater in Alox15 transgenic mice than in WT mice. *, P < 0.05 
versus WT. Results represent the mean ± SEM of three independent 
experiments; n = 6. (B–D) Cardiac fibroblasts (B), endothelial cells (C), 
and cardiomyocytes (D) were treated with 5 × 107 M 12(S)-HETE for the 
indicated times (0–24 h), and expression of Ccl2 was examined by the 
ribonuclease protection assay. Graphs display relative expression of Ccl2. 
Incubation with 12(S)-HETE increased Ccl2 expression by cardiac fibro-
blasts and endothelial cells. *, P < 0.01 versus time 0. Results represent 
mean ± SEM of four independent experiments; n = 4 for B and C; n = 7 
for D. (E) The luciferase reporter gene plasmid containing the B binding 
site was transfected into COS7 cells, which were cultured in the absence 
or presence of 5 × 107 M 12(S)-HETE. The luciferase assay was per-
formed 12 h later. A reporter plasmid containing the mutant B binding 
site was used as the negative control. Incubation of cells with 12(S)-HETE 
significantly increased the activity of nuclear factor B. *, P < 0.01 versus 
12(S)-HETE ()/B. Results represent the mean ± SEM of five indepen-
dent experiments; n = 6.1570 12/15-LIPOXYGENASE IN HEART FAILURE | Kayama et al.
induces up-regulation of MCP-1 expression in the setting of 
pressure overload, thereby increasing cardiac inflammation 
and leading to systolic dysfunction. Consistent with our find-
ings, inhibition of MCP-1 has been reported to attenuate 
Figure 4.  Inhibition of MCP-1 prevents cardiac dysfunction in Alox15 transgenic animals. (A) The plasma levels of 7ND (human MCP-1) and 
murine MCP-1 were determined by ELISA at the indicated times after introduction of the 7ND expression vector. The plasma level of human MCP-1 was 
significantly increased after injection of the 7ND plasmid. *, P < 0.01 versus day 0; #, P < 0.01 versus day 3. Results represent the mean ± SEM of three 
independent experiments; n = 5. (B) Number of Mac3-positive cells in the hearts of WT mice, transgenic (Tg) mice, and transgenic mice treated with 7ND 
(Tg + 7ND). Injection of the 7ND plasmid reduced the myocardial infiltration of macrophages in Alox15 transgenic mice. (C) Echocardiographic findings in 
WT mice, transgenic mice, and transgenic mice treated with 7ND (Tg + 7ND). Injection of the 7ND plasmid prevented systolic dysfunction and left ven-
tricular dilatation in Alox15 transgenic mice. *, P < 0.05; **, P < 0.01 versus WT; #, P < 0.05; ##, P < 0.01 versus transgenic. Results represent mean ± SEM 
of three independent experiments. B, n = 7; C, n = 10–14.
Figure 5.  Cardiac expression of 12/15-LOX is up-regulated during pressure overload. (A) Echocardiographic findings in WT and Alox15-deficient 
(KO) mice on day 7 (D7) and day 14 (D14) after TAC surgery. FS was preserved until day 7 but was significantly decreased on day 14 along with left ven-
tricular dilatation in WT mice. Disruption of Alox15 (KO) significantly improved systolic dysfunction and prevented left ventricular dilatation caused by 
chronic pressure overload. LVDs, left ventricular systolic dimension; sham, sham operation. *, P < 0.01 versus sham; #, P < 0.05; ##, P < 0.01 versus WT. 
Results represent the mean ± SEM of three independent experiments; n = 10. (B and C) Alox15 expression (B) and the 12/15(S)-HETE level (C) were exam-
ined in the hearts of WT mice on day 7 (D7) and day 14 (D14) after TAC surgery by real-time PCR and ELISA, respectively. Cardiac expression of 12/15-LOX 
was significantly up-regulated after TAC, and production of both 12(S)-HETE and 15(S)-HETE was increased in the heart. *, P < 0.01 versus sham; #, P < 0.01 
versus D7. Results represent the mean ± SEM of three independent experiments; n = 6.
have  a  major  role  in  promoting  cardiac  inflammation  in 
Alox15 transgenic mice because its inhibition almost com-
pletely abolished the accumulation of macrophages and pre-
vented systolic dysfunction. We also showed that 12/15-LOX JEM VOL. 206, July 6, 2009 
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dysfunction (Kolattukudy et al., 1998). In agreement with our 
in vitro data, it has been reported that MCP-1 expression is 
up-regulated in vascular endothelial cells and fibroblasts by 
pressure overload (Kuwahara et al., 2004). Collectively, these 
myocardial inflammation, fibrosis, and cardiac dysfunction 
induced by chronic pressure overload (Kuwahara et al., 2004). 
It has also been reported that transgenic animals with cardiac 
expression of MCP-1 develop myocardial fibrosis and systolic 
Figure 6.  Disruption of Alox15 attenuates cardiac inflammation during pressure overload. (A) Double immunostaining for 12/15-LOX (red) and 
actinin (green) in the hearts of sham-operated WT mice (WT sham), WT mice with TAC (WT TAC), and Alox15-deficient mice with TAC (KO TAC). Increased 
expression of 12/15-LOX was observed in cardiomyocytes after TAC in WT mice but not KO mice. Nuclei were stained with DAPI (blue). Bars, 20 µm. Re-
sults are representative of four independent experiments. (B) 12/15(S)-HETE levels were examined in the hearts of WT and Alox15-deficient (KO) mice 
after sham surgery or TAC. The increase of 12(S)-HETE and 15(S)-HETE production after TAC was markedly attenuated in Alox15-deficient mice (KO).  
*, P < 0.01 versus WT sham; #, P < 0.01 versus WT TAC. Results represent the mean ± SEM of three independent experiments; n = 6–8. (C) Expression of 
Ccl2 (MCP-1) and Cd68 was examined in the hearts of WT and Alox15-deficient (KO) mice after sham surgery or TAC. Expression of both genes was in-
creased by about threefold at 14 d after TAC. This increase of expression was significantly inhibited by disruption of Alox15. *, P < 0.01 versus WT sham;  
#, P < 0.01 versus WT TAC. Results represent the mean ± SEM of three independent experiments; n = 6–8.1572 12/15-LIPOXYGENASE IN HEART FAILURE | Kayama et al.
in the failing heart could induce systemic inflammation and 
have a detrimental effect on other inflammatory diseases such 
as atherosclerosis, metabolic syndrome, and nephropathy. 
Conversely, inhibition of 12/15-LOX could be an attractive 
new strategy for the treatment of heart failure, as well as vari-
ous other inflammatory conditions.
Materials and Methods
Animal  models. All of the experimental protocols were approved by 
Chiba University review board. Male Dahl salt-sensitive (DS) rats were 
purchased from SLC. The rats were fed a low-sodium diet until the age of 
6 wk and then a high-sodium diet (8% NaCl) throughout the experimental 
period. In this model, marked cardiac hypertrophy developed and left ven-
tricular systolic function was impaired at 17 wk of age. Accordingly, DS rats 
were sacrificed for gene chip analysis at 17 wk. All of the DS rats given a 
high-sodium diet showed signs of heart failure such as rapid and labored 
respiration and diffuse left ventricular hypokinesis on echocardiography at 
the time of sacrifice. Other DS rats were fed a low-salt diet (0.3% NaCl) as 
a control group.
We generated transgenic mice on a C57BL/6 background that expressed 
12/15-LOX in cardiomyocytes under the control of the –cardiac myosin 
heavy chain (-MHC) promoter. A mouse Alox15 complementary DNA 
(cDNA)  fragment  (gift  from  C.D.  Funk,  University  of  Pennsylvania, 
Philadelphia, PA) fused with the HA tag was subcloned into the -MHC pro-
moter vector. The transgene was identified by genomic PCR with transgene-
specific  oligonucleotide  primers  (5-CCACACCAGAAATGACAGAC-3 
and 5-GCGGGCAGGGAGACAAGTAG-3) and by Southern blot analysis. 
Two independent lines of Alox15 transgenic mice (lines 711 and 716) 
were obtained. The cardiac phenotype was similar in both lines of transgenic 
animals. WT littermates were used as the control for all experiments.
Alox15-deficient mice on a C57BL/6 background were purchased from 
The Jackson Laboratory. WT littermates served as a control for all experi-
ments. TAC was performed as described previously (Sano et al., 2007) on 
10–11-wk-old male mice. Sham-operated mice underwent the same proce-
dure without aorta constriction.
An expression vector encoding mutant human MCP-1 with deletion of 
N-terminal amino acids (7ND plasmid) was prepared as described elsewhere 
(Hayashidani et al., 2003). Under anesthesia, mice received an injection of 
100 µg of either the empty vector or the 7ND plasmid in PBS into the bilat-
eral tibial muscles using a 27-gauge needle fitted with a plastic collar that 
limited muscle penetration to 5 mm. Injection was performed every 2 wk 
from 10 wk until 48 wk of age. To increase the efficiency of gene transfec-
tion, 100 µl of the myotoxic agent bupivacaine (0.25% wt/vol) was injected 
into the muscles 3 d before transfection. Transfection of 7ND leads to an in-
crease of mutant MCP-1 in the blood, as indicated by elevation of its plasma 
concentration after 14 d. The circulating mutant MCP-1 binds to the recep-
tor for MCP-1 (chemokine receptor 2) on target cells and effectively blocks 
MCP-1 signaling (Ni et al., 2001; Hayashidani et al., 2003).
Physiological  and  histological  analysis.  Echocardiography  was  per-
formed with a Vevo 770 High Resolution Imaging System (Visual Sonics 
Inc.). To minimize variation of the data, the heart rate was 500-600 beats 
per minute when cardiac function was assessed. The peak systolic blood 
pressure was recorded by a photoelectric pulse devise (Blood Pressure Meter 
BP-98A; Softron Co. Ltd.) placed on the tails of unanesthetized mice. Un-
der anesthesia, a micropressure transducer with an outer diameter of 0.42 
mm (Samba 201 control unit and Samba Preclin 420 transducer; Samba Sen-
sors AB) was introduced into the right carotid artery. Pressure signals were 
recorded with a MacLab 3.6/s data acquisition system (AD Instruments) at a 
sampling rate of 2,000 Hz. 4-µm frozen cross sections of the heart were fixed 
in 4% paraformaldehyde and subjected to Masson trichrome staining or im-
munohistochemistry  for  Mac3  (BD).  Digital  photographs  were  taken  at 
400× magnification of 25 random fields from each heart, and the number of 
Mac3-positive cells was counted in each field. The frozen cardiac cross sections 
results indicate that chronic pressure overload increases the 
expression of 12/15-LOX, which then causes heart failure by 
promoting cardiac inflammation and fibrosis.
Target gene disruption or overexpression of 12/15-LOX 
in mice with a genetic background of apolipoprotein E or 
low-density lipoprotein receptor deficiency has shown that 
this enzyme may have a role in atherogenesis. The data indi-
rectly support a role for 12/15-LOX in the oxidative modifi-
cation of low-density lipoprotein. Consistent with our results, 
recent evidence suggests that 12/15-LOX plays a crucial role 
in the regulation of proinflammatory molecules and that this 
regulatory activity of 12/15-LOX may be important for link-
ing 12/15-LOX activation to atherogenesis. For example, 
12(S)-HETE increases the expression of MCP-1, interleukin 
6, tumor necrosis factor , and adhesion molecules by mac-
rophages and vascular cells (Bolick et al., 2005, 2006; Wen et al., 
2007, 2008; Dwarakanath et al., 2008), and these changes are 
partly mediated by activation of nuclear factor B (Bolick 
et al., 2005, 2006; Dwarakanath et al., 2008). Disruption of 
12/15-LOX has also been shown to attenuate airway allergic 
inflammation by modulating the expression of proinflamma-
tory cytokines (Andersson et al., 2008).
The mechanism of 12/15-LOX activation in the failing 
heart is unclear. We previously demonstrated that mismatch 
between the number of capillaries and the size of cardiomyo-
cytes occurs during the development of cardiac hypertrophy, 
leading to myocardial hypoxia and systolic dysfunction (Sano 
et al., 2007). Because exposure of cultured cardiomyocytes to 
hypoxia up-regulates 12/15-LOX expression (unpublished 
data), a hypoxic state might be one reason for the induction of 
12/15-LOX in the failing heart. This concept is supported by 
previous results that hypoxia up-regulates 12/15-LOX expres-
sion in the lungs and the brain (Bernaudin et al., 2002; Zhu 
et al., 2003a). Moreover, we have found that 12/15-LOX ex-
pression is significantly up-regulated in the heart after myocar-
dial infarction (unpublished data). There are putative binding 
elements for CCAAT/enhancer binding proteins and nuclear 
factor B within the promoter region of the Alox15 gene (un-
published data), and both of these molecules are known to be 
activated by hypoxia (Cummins and Taylor, 2005).
Inflammation has an important role in the pathogenesis 
and  progression  of  many  forms  of  heart  failure,  and  bio-
markers of inflammation have become the subject of intense 
investigation. In the Framingham Heart Study, an increase of 
C-reactive protein (as well as inflammatory cytokines such as 
interleukin 6 and tumor necrosis factor ) was found to iden-
tify asymptomatic older persons in the community with a 
high risk of developing heart failure in the future (Braunwald, 
2008). Multivariate analysis has shown that an increase of 
C-reactive protein is an independent predictor of adverse 
outcomes  in  patients  with  acute  or  chronic  heart  failure 
(Anand et al., 2005), suggesting that heart failure is closely as-
sociated with systemic inflammation. Because metabolites of 
12/15-LOX may have a role in vascular inflammation, insu-
lin resistance, and renal dysfunction (Natarajan and Nadler, 
2004; Kuhn and O’Donnell, 2006), activation of 12/15-LOX JEM VOL. 206, July 6, 2009 
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Online supplemental material. Fig. S1 depicts Alox15 transgenic animal 
data. Fig. S2 shows MCP-1 levels after treatment with 7ND. Fig. S3 shows 
a negative control of immunohistochemistry for 12/15-LOX. Fig. S4 shows 
blood pressure of Alox15-deficient mice. Table S1 summarizes the microar-
ray data. Online supplemental material is available at http://www.jem.org/ 
cgi/content/full/jem.20082596/DC1.
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